Intezyne Receives Intent-to-Grant Notice from the European Patent Office

http://www.businesswire.com/news/home/20100422005253/en

TAMPA, Fla.--(Business Wire)--
Intezyne today announced it has received notification the European Patent Office
intends to grant a patent covering a key element of Intezyne`s breakthrough drug
delivery technology, the IVECT Method. At the core of this technology is the
IVECT micelle, a proprietary, polymeric nanoparticle designed to encapsulate and
deliver best-in-class therapeutics, while limiting exposure to healthy tissues.
The IVECT Method is already covered by seven additional patents both in the
United States and worldwide. This wide-ranging, European patent covers
technology that allows greater flexibility and versatility of the IVECT micelle,
particularly with respect to the amount of hydrophobic material that can be
encapsulated into this drug delivery vehicle, further bolstering Intezyne`s
intellectual property portfolio.

Hybrid Block Copolymers With Mixed Stereochemistry for Encapsulation of Hydrophobic Agents
- Sill, K.; Skaff, H.; Breitenkamp, K.
- EU patent number: EP2073850
- Issued claims include composition of matter for Intezyne`s proprietary triblock
copolymers, which utilize both D- and L-isomers in the encapsulation block.

"Historically, encapsulating highly hydrophobic drugs has proven to be a major
stumbling block for the great majority of drug delivery systems," explained
Kevin Sill, Ph.D., Chief Scientific Officer of Intezyne. "The advanced
technology covered by this patent protects Intezyne`s ability to encapsulate
hydrophobic drugs more efficiently. Further, we have shown for the first time
IVECT micelles are able to encapsulate several hydrophobic compounds that were
previously intractable to delivery methods at therapeutically relevant levels."

Intezyne is active in its efforts to prosecute its patents and protect its
intellectual property in major global pharmaceutical markets. The above patent
currently is being prosecuted in the United States, as well as Australia,
Canada, Israel, India, Japan, Mexico, and New Zealand.

All granted and pending patent applications are wholly owned by Intezyne.

About Intezyne

Intezyne is dedicated to treating cancer better by offering a new solution to
oncologists, who must balance the anti-tumor activity of best-in-class
chemotherapeutics with their severe toxicities. Drawing from their expertise in
polymer chemistry, the Company`s founders created the IVECT Method to limit
chemotherapeutics` anti-tumor activity to within the tumor itself, thereby
sparing healthy tissues. To date, the IVECT Method has shown positive
preclinical efficacy and safety profiles in multiple cancer models versus
best-in-class chemotherapeutic agents. Ultimately, the IVECT Method has
demonstrated preclinical proof-of-concept in a number of therapeutic and
diagnostic categories, giving the Company the opportunity to monetize this asset
through licensing agreements outside of Intezyne`s primary oncology focus.

About the IVECT Method

Intezyne`s IVECT Method is a unique and remarkably safe platform that has the
potential to raise the bar in terms of what patients and oncologists can expect
from chemotherapy. The key to this breakthrough technology is the Company`s
multi-disciplinary approach, integrating polymer physics and materials science
with organic chemistry, polymer chemistry, biochemistry, and biology. Intezyne
can improve patient outcomes significantly by amplifying the efficacy and safety
profiles of best-in-class cancer drugs, whose potency often is handicapped by
nonspecific delivery outside of the tumor site, requiring higher dosing and
resulting in severe toxicities. The IVECT Method has proven to be
extraordinarily versatile, in terms of the diversity of materials that can be
encapsulated securely, and its unique modular design confers unmatched
adaptability at a minimal cost. Beyond chemotherapy, the Company has proven the
IVECT Method can deliver many classes of small molecules, in addition to nucleic
acids, oligopeptides, and diagnostic imaging agents.

For more information, please visit www.intezyne.com.

Intezyne
Habib Skaff, 813-910-2120
habib.skaff@intezyne.com
or
Burns McClellan
For Investors:
Juliane Snowden, 212-213-0006
jsnowden@burnsmc.com
or
For Media:
Justin Jackson, 212-213-0006
jjackson@burnsmc.com

Copyright Business Wire 2010